Exploiting Common Genetic Variation to Make Anticoagulation Safer

被引：15

作者：

Chang, Yuchiao ^{[1
]}

Cortellini, Lynelle ^{[1
]}

Greenberg, Steven M. ^{[1
]}

Rosand, Jonathan ^{[1
]}

Singer, Daniel ^{[1
]}

Schwab, Kristen ^{[1
]}

Selim, Magdy ^{[2
]}

Meschia, James ^{[3
]}

Eckman, Mark H. ^{[4
]}

Silliman, Scott ^{[5
]}

Brown, Devon ^{[6
]}

Worrall, W. Bradford ^{[7
]}

Tirschwell, David ^{[8
]}

Gage, Brian F. ^{[9
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[3] Mayo Clin, Jacksonville, FL 32224 USA

[4] Univ Cincinnati, Cincinnati, OH 45221 USA

[5] Univ Florida, Gainesville, FL 32611 USA

[6] Univ Michigan, Ann Arbor, MI 48109 USA

[7] Univ Virginia, Charlottesville, VA 22903 USA

[8] Univ Washington, Seattle, WA 98195 USA

[9] Washington Univ, St Louis, MO 63130 USA

来源：

STROKE | 2009年 / 40卷 / 03期

关键词：

anticoagulation; ATRIAL-FIBRILLATION; CYTOCHROME P450CYP2C9-ASTERISK-2; CYP2C9-ASTERISK-3; ALLELES; HEMORRHAGIC COMPLICATIONS; INTRACEREBRAL HEMORRHAGE; BLEEDING COMPLICATIONS; WARFARIN THERAPY; RISK; CYP2C9; POLYMORPHISMS;

D O I：

10.1161/STROKEAHA.108.533190

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S64 / S66

页数：3

共 18 条

[1] Adcock DM, 2004, ARCH PATHOL LAB MED, V128, P1360
[2] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
Aithal, GP
Day, CP
Kesteven, PJL
Daly, AK
[J]. LANCET, 1999, 353 (9154) : 717 - 719
[3] Patient-Specific Decision-Making for Warfarin Therapy in Nonvalvular Atrial Fibrillation How Will Screening With Genetics and Imaging Help?
Eckman, Mark H.
Wong, Lawrence K. S.
Soo, Yannie O. Y.
Lam, Wynnie
Yang, Song Ran
Greenberg, Steven M.
Rosand, Jonathan
[J]. STROKE, 2008, 39 (12) : 3308 - 3315
[4] Death and disability from warfarin-associated intracranial and extracranial hemorrhages
Fang, Margaret C.
Go, Alan S.
Chang, Yuchiao
Hylek, Elaine M.
Henault, Lori E.
Jensvold, Nancy G.
Singer, Daniel E.
[J]. AMERICAN JOURNAL OF MEDICINE, 2007, 120 (08) : 700 - 705
[5] Age and the risk of warfarin-associated hemorrhage: The anticoagulation and risk factors in atrial fibrillation study
Fang, Margaret C.
Go, Alan S.
Hylek, Elaine M.
Chang, Yuchiao
Henault, Lori E.
Jensvold, Nancy G.
Singer, Daniel E.
[J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (08) : 1231 - 1236
[6] Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation
Fang, MC
Chang, YC
Hylek, EM
Rosand, J
Greenberg, SM
Go, AS
Singer, DE
[J]. ANNALS OF INTERNAL MEDICINE, 2004, 141 (10) : 745 - 752
[7] Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
Higashi, MK
Veenstra, DL
Kondo, LML
Wittkowsky, AK
Srinouanprachanh, SL
Farin, FM
Rettie, AE
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13): : 1690 - 1698
[8] Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin
Limdi, Na
McGwin, G.
Goldstein, J. A.
Beasley, T. M.
Arnett, D. K.
Adler, B. K.
Baird, M. F.
Acton, R. T.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) : 312 - 321
[9] Margaglione M, 2000, THROMB HAEMOSTASIS, V84, P775
[10] The effect of warfarin and intensity of anticoagulation on outcome of intracerebral Hemorrhage
Rosand, J
Eckman, MH
Knudsen, KA
Singer, DE
Greenberg, SM
[J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (08) : 880 - 884

← 1 2 →